1O'Brien E,Wseber B,Parati G,et al.Blood pressure measuring devices:recommendations of the European Society of Hyertension[J].BMJ,2001,322(7285):531 -536.
2王文.高血压综合防治研究新进展[M].北京:中华医学电子音像出版社,2007.32-37.
3Staessen JA,O'Brien ET,Thijs L,et al.Modern approaches to blood presseure measurement[J].Occup Environ Med,2000,57(8):510-520.
5Mancia G,Parati G.Clinical significance of "White coat" hypertension[J].Hypertension,1990,16:624-625.
6Zacharich PK,Krier JD.Chinical use of ambulatory blood pressure monitoring[J].Hypertens,1991,9(suppl1):1-11.
7Sega R,Trocino G,lanzarotti A,et al.Alterations of cardiac structure in patients with isolated office,ambulatory,or home hypertension:data from the general poplation (Pre-ssioni Arteriose Monitor ate E Loro Associazioni[PAMEELA] Study)[J].Circulation,2001,104:1385-1395.
9Ugajin T,Hozawa A,Ohkubo T,et al.Whitecoat hypertension as a risk factor for the development of home hypertension:the Ohasama study[J].Arch Interm Med,2005,165:1541-1546.
3Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J,2007,28 : 1462 - 1536.
4Weber MA, Julius S, Kjeldsen SE,et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial[ J]. Lancet,2004,363:2049- 2051.
5Pepine C J, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease [J]. J Am Coll Cardiol,2006,47:547 -551.
6Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[ J ]. Lancet, 2004,363:2022 - 2031.
7Dahlof B, Sever PS, Pouher NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomised controlled trial [J].Lancet,2005,366 : 895 - 906.
8Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group [ J ]. Jama, 2000,283 : 1967 - 1975.
9Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved trial [ J ]. Lancet, 2003, 362:777 -781.
